Novartis names Sandoz board members ahead of spin-off
ZURICH (Reuters) – Novartis on Monday named the intended new board members of Sandoz, the generics business it plans to spin off to shareholders later this year. The Basel company approved the recommendations of Sandoz Chairman-designate Gilbert Ghostine for the 10 members of the board, which will start preparatory work in June. The new members…
